MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes.
Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical's lead management portfolio, enhance Merit's product portfolio and offer longer-term synergies.
Merit Medical aims to improve care for vulnerable premature infants by evaluating the safety and efficacy of the Bloom Micro Occluder System for treating PDA in the specified patient pool.
Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.81 per share a year ago.
Evaluate the expected performance of Merit Medical (MMSI) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Merit Medical (MMSI) could produce exceptional returns because of its solid growth attributes.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merit Medical (MMSI) possesses solid growth attributes, which could help it handily outperform the market.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.